Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 3/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL27648412 | 0.91 | CES1 (0.42) | CES1CES2AKR1B1CTBP2MIF | |
| Toluene SCHEMBL29217701 | 0.91 | L3MBTL1 (0.45) | CES1CES2AKR1B1CTBP2MIF | |
| SCHEMBL1357419 | 0.82 | CES1 (0.52) | CES1CES2AKR1B1CTBP2ALDH1A1 | |
| Toluene SCHEMBL4327028 | 0.81 | SMN1; SMN2 (0.44) | CTBP2MIFALDH1A1CYP3A4HPGD | |
| SCHEMBL3567707 | 0.81 | KEAP1 (0.53) | MIFTRPA1ALDH1A1HDAC8HDAC6 | |
| SCHEMBL3574828 | 0.81 | CTBP2 (0.47) | CTBP2MIFALDH1A1CYP3A4HPGD | |
| SCHEMBL5825140 | 0.81 | CES2 (0.39) | CES1CES2CTBP2MIFTRPA1 | |
| SCHEMBL16280718 | 0.81 | CTBP2 (0.47) | CTBP2ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL105873 | 0.81 | MIF (0.48) | CTBP2MIFALDH1A1KMT2AFFAR1 | |
| SCHEMBL27825858 | 0.80 | CTBP2 (0.51) | CTBP2ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | claimed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | claimed |
| CN-115087637-A | Process for producing acylthiourea compound | 大鹏药品工业株式会社 | 2022-09-20 | — | — | CN | claimed |
| WO-2021162096-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | 大鵬薬品工業株式会社 | 2021-08-19 | — | — | WO | claimed |
| CN-117800908-A | Edge-like substance of thiosemicarbazide compound | 大鹏药品工业株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115103834-A | Kindred material of thiosemicarbazide compound | 大鹏药品工业株式会社 | 2022-09-23 | — | — | CN | disclosed |
| CN-115087637-A | Process for producing acylthiourea compound | 大鹏药品工业株式会社 | 2022-09-20 | — | — | CN | disclosed |
| CN-115087637-A | Process for producing acylthiourea compound | 大鹏药品工业株式会社 | 2022-09-20 | — | — | CN | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-0092391-A2 | Novel piperidine derivatives and pharmaceutical compositions containing same | KYOWA HAKKO KOGYO CO., LTD (JP) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CES1 3676/4885CES2 4799/4885AKR1B1 1143/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | CES1 1862/4885CES2 4812/4885AKR1B1 310/4885 |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | AGPAT2, ACAT2, AADAC | CES1 1443/4885CES2 326/4885AKR1B1 2394/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | CES1 2399/4885CES2 1425/4885AKR1B1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.